Access Pharma's CEO Interviewed By Proactive Investors Group

DALLAS and NEW YORK, April 19 /PRNewswire-FirstCall/ -- Jeffrey Davis, President and CEO of ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, was recently interviewed by the Proactive Investors Group, an international financial media company.  In the interview, Davis provides an overview of Access Pharma's robust product pipeline, an update on the global rollout of its FDA-approved product MuGard, and discusses the Company's ongoing multi-faceted approach to build value for shareholders.  

The audio interview is now live and can be accessed using the following links:

http://www.proactiveinvestors.com/companies/news/5388/jeffrey-davis-ceo-of-access-pharmaceuticals-talks-about-a-product-for-cancer-patients-and-trials-of-orally-administered-insulin-5388.html

http://www.youtube.com/watch?v=tXbtDMPg3-0

About MuGard:

MuGard is a novel, ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase II clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with oral mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

SOURCE Access Pharmaceuticals, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED